Literature DB >> 23187830

Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.

Ai Mogi1, Kaori Koga, Mikiko Aoki, Makoto Hamasaki, Noriko Uesugi, Akinori Iwasaki, Takayuki Shirakusa, Kazuo Tamura, Kazuki Nabeshima.   

Abstract

Malignant cells supply their energy needs through increased glucose consumption, producing large quantities of lactic acid via glycolysis. Glucose transporters (GLUTs) and monocarboxylate transporters (MCTs) are therefore commonly up-regulated in human malignancies to mediate glucose influx and lactic acid efflux, respectively. However, their roles in malignant pleural mesothelioma (MPM) have not been fully elucidated. Here, we evaluated GLUT-1, MCT-1, and MCT-4 expression in human MPM and reactive mesothelial hyperplasia (RMH) and elucidated their biological role in vitro. GLUT-1, MCT-1, and MCT-4 expression was determined in human MPM (n = 35) and RMH (n = 20) specimens by immunohistochemistry and in frozen tissue, and MPM cell lines, by real-time reverse transcription-polymerase chain reaction and western blot analysis. GLUT-1, MCT-1, and MCT-4 functions in MPM were evaluated by transfection with small interfering RNA. Immunohistochemical analysis revealed higher levels of GLUT-1, MCT-1, and MCT-4 in MPM than in RMH. Additionally, GLUT-1, MCT-1, and MCT-4 mRNA levels were higher in MPM than in non-neoplastic mesothelial cell lines. The siRNA-mediated knockdown of GLUT-1 or MCT-1 significantly suppressed tumor cell proliferation, and MCT-1 silencing inhibited invasion and induced apoptosis. Taken together, these results indicate that combined application of GLUT-1, MCT-1, and MCT-4 immunohistochemistry might be useful in differentiating MPM from RMH and suggest that MCT-1plays an important biological role.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23187830     DOI: 10.1007/s00428-012-1344-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  30 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Psoriasin (S100A7) expression and invasive breast cancer.

Authors:  S Al-Haddad; Z Zhang; E Leygue; L Snell; A Huang; Y Niu; T Hiller-Hitchcock; K Hole; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.

Authors:  Yasufumi Kato; Koji Tsuta; Kunihiko Seki; Akiko Miyagi Maeshima; Shunichi Watanabe; Kenji Suzuki; Hisao Asamura; Ryosuke Tsuchiya; Yoshihiro Matsuno
Journal:  Mod Pathol       Date:  2006-12-22       Impact factor: 7.842

4.  The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.

Authors:  Sara E Monaco; Yongli Shuai; Mona Bansal; Alyssa M Krasinskas; Sanja Dacic
Journal:  Am J Clin Pathol       Date:  2011-04       Impact factor: 2.493

5.  Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Adrian L Harris; Efthimios Sivridis
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 6.  The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation.

Authors:  A P Halestrap; N T Price
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

7.  Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma.

Authors:  Céline Pinheiro; André Albergaria; Joana Paredes; Bárbara Sousa; Rozany Dufloth; Daniella Vieira; Fernando Schmitt; Fátima Baltazar
Journal:  Histopathology       Date:  2010-06       Impact factor: 5.087

8.  Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study.

Authors:  Saroj P Mathupala; Prahlad Parajuli; Andrew E Sloan
Journal:  Neurosurgery       Date:  2004-12       Impact factor: 4.654

9.  Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study.

Authors:  R S Brown; R L Wahl
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

10.  Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; Cristovam Scapulatempo; Luísa Ferreira; Sandra Martins; Luc Pellerin; Mesquita Rodrigues; Venancio A F Alves; Fernando Schmitt; Fátima Baltazar
Journal:  Virchows Arch       Date:  2008-01-10       Impact factor: 4.064

View more
  7 in total

Review 1.  Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment.

Authors:  Mohd Rihan; Lakshmi Vineela Nalla; Anil Dharavath; Amit Shard; Kiran Kalia; Amit Khairnar
Journal:  Cancer Microenviron       Date:  2019-06-10

2.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

3.  Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis.

Authors:  Zheng-Xiao Zhao; Lin-Wei Lu; Jian Qiu; Qiu-Ping Li; Fei Xu; Bao-Jun Liu; Jing-Cheng Dong; Wei-Yi Gong
Journal:  Oncotarget       Date:  2017-07-04

4.  Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report).

Authors:  Irene Dell'Anno; Elisa Barone; Luciano Mutti; Doris M Rassl; Stefan J Marciniak; Roberto Silvestri; Stefano Landi; Federica Gemignani
Journal:  J Transl Med       Date:  2020-09-04       Impact factor: 5.531

5.  MCTS1 as a Novel Prognostic Biomarker and Its Correlation With Immune Infiltrates in Breast Cancer.

Authors:  Mei Deng; Chao Xiong; Zhuo-Kai He; Qiong Bin; Jing-Zhi Song; Wei Li; Jie Qin
Journal:  Front Genet       Date:  2022-02-28       Impact factor: 4.599

6.  Energy Substrate Transporters in High-Grade Ovarian Cancer: Gene Expression and Clinical Implications.

Authors:  Marta Baczewska; Elżbieta Supruniuk; Klaudia Bojczuk; Paweł Guzik; Patrycja Milewska; Katarzyna Konończuk; Jakub Dobroch; Adrian Chabowski; Paweł Knapp
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

7.  Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Authors:  Nicola J Curtis; Lorraine Mooney; Lorna Hopcroft; Filippos Michopoulos; Nichola Whalley; Haihong Zhong; Clare Murray; Armelle Logie; Mitchell Revill; Kate F Byth; Amanda D Benjamin; Mike A Firth; Stephen Green; Paul D Smith; Susan E Critchlow
Journal:  Oncotarget       Date:  2017-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.